Baxter International Inc. (BAX) Stock Competitors & Peer Comparison
See (BAX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAX | $18.54 | -0.75% | 9.6B | -9.71 | -$1.91 | +1.08% |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.42% |
| BDX | $145.61 | +0.82% | 52.8B | 25.42 | $5.73 | +2.42% |
| ALC | $64.22 | -0.09% | 31.3B | 38.46 | $1.67 | +0.56% |
| MDLN | $34.47 | +3.86% | 29.1B | 30.24 | $1.14 | N/A |
| WST | $316.31 | +1.33% | 22.4B | 42.25 | $7.49 | +0.28% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.42% |
| COO | $60.34 | +1.43% | 11.8B | 30.01 | $2.01 | N/A |
| ATR | $112.53 | +0.31% | 7.2B | 19.27 | $5.84 | +1.68% |
Stock Comparison
BAX vs BDXA Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BAX is priced at $18.54, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas BDXA's P/E ratio is 21.44. In terms of profitability, BAX's ROE is -0.16%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, BAX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check BDXA's competition here
BAX vs BDX Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, BDX has a market cap of 52.8B. Regarding current trading prices, BAX is priced at $18.54, while BDX trades at $145.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas BDX's P/E ratio is 25.42. In terms of profitability, BAX's ROE is -0.16%, compared to BDX's ROE of +0.05%. Regarding short-term risk, BAX is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check BDX's competition here
BAX vs ALC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ALC has a market cap of 31.3B. Regarding current trading prices, BAX is priced at $18.54, while ALC trades at $64.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ALC's P/E ratio is 38.46. In terms of profitability, BAX's ROE is -0.16%, compared to ALC's ROE of +0.04%. Regarding short-term risk, BAX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ALC's competition here
BAX vs MDLN Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, MDLN has a market cap of 29.1B. Regarding current trading prices, BAX is priced at $18.54, while MDLN trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas MDLN's P/E ratio is 30.24. In terms of profitability, BAX's ROE is -0.16%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BAX is less volatile compared to MDLN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check MDLN's competition here
BAX vs WST Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, WST has a market cap of 22.4B. Regarding current trading prices, BAX is priced at $18.54, while WST trades at $316.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas WST's P/E ratio is 42.25. In terms of profitability, BAX's ROE is -0.16%, compared to WST's ROE of +0.18%. Regarding short-term risk, BAX is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check WST's competition here
BAX vs HOLX Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BAX is priced at $18.54, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BAX's ROE is -0.16%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check HOLX's competition here
BAX vs BDXB Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BAX is priced at $18.54, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BAX's ROE is -0.16%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, BAX is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check BDXB's competition here
BAX vs COO Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, COO has a market cap of 11.8B. Regarding current trading prices, BAX is priced at $18.54, while COO trades at $60.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas COO's P/E ratio is 30.01. In terms of profitability, BAX's ROE is -0.16%, compared to COO's ROE of +0.05%. Regarding short-term risk, BAX is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check COO's competition here
BAX vs ATR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ATR has a market cap of 7.2B. Regarding current trading prices, BAX is priced at $18.54, while ATR trades at $112.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ATR's P/E ratio is 19.27. In terms of profitability, BAX's ROE is -0.16%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATR's competition here
BAX vs RGEN Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, RGEN has a market cap of 6.9B. Regarding current trading prices, BAX is priced at $18.54, while RGEN trades at $121.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas RGEN's P/E ratio is 133.79. In terms of profitability, BAX's ROE is -0.16%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BAX is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check RGEN's competition here
BAX vs AVTR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, AVTR has a market cap of 6.2B. Regarding current trading prices, BAX is priced at $18.54, while AVTR trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas AVTR's P/E ratio is -11.21. In terms of profitability, BAX's ROE is -0.16%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BAX is less volatile compared to AVTR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check AVTR's competition here
BAX vs TFX Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, BAX is priced at $18.54, while TFX trades at $128.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas TFX's P/E ratio is 2143.17. In terms of profitability, BAX's ROE is -0.16%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BAX is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check TFX's competition here
BAX vs BLCO Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, BLCO has a market cap of 5.3B. Regarding current trading prices, BAX is priced at $18.54, while BLCO trades at $14.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas BLCO's P/E ratio is -23.95. In terms of profitability, BAX's ROE is -0.16%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BAX is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check BLCO's competition here
BAX vs STVN Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, STVN has a market cap of 5.1B. Regarding current trading prices, BAX is priced at $18.54, while STVN trades at $18.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas STVN's P/E ratio is 31.53. In terms of profitability, BAX's ROE is -0.16%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BAX is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STVN's competition here
BAX vs MMSI Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, MMSI has a market cap of 3.6B. Regarding current trading prices, BAX is priced at $18.54, while MMSI trades at $60.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas MMSI's P/E ratio is 26.14. In terms of profitability, BAX's ROE is -0.16%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check MMSI's competition here
BAX vs ICUI Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ICUI has a market cap of 3.3B. Regarding current trading prices, BAX is priced at $18.54, while ICUI trades at $130.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ICUI's P/E ratio is 70.17. In terms of profitability, BAX's ROE is -0.16%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BAX is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ICUI's competition here
BAX vs HAE Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, HAE has a market cap of 3B. Regarding current trading prices, BAX is priced at $18.54, while HAE trades at $65.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas HAE's P/E ratio is 32.13. In terms of profitability, BAX's ROE is -0.16%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check HAE's competition here
BAX vs WRBY Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, WRBY has a market cap of 3B. Regarding current trading prices, BAX is priced at $18.54, while WRBY trades at $24.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas WRBY's P/E ratio is 2422.05. In terms of profitability, BAX's ROE is -0.16%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, BAX is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check WRBY's competition here
BAX vs LMAT Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, LMAT has a market cap of 2.1B. Regarding current trading prices, BAX is priced at $18.54, while LMAT trades at $91.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas LMAT's P/E ratio is 33.72. In terms of profitability, BAX's ROE is -0.16%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BAX is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check LMAT's competition here
BAX vs XRAY Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, BAX is priced at $18.54, while XRAY trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas XRAY's P/E ratio is -3.06. In terms of profitability, BAX's ROE is -0.16%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BAX is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check XRAY's competition here
BAX vs NVCR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, BAX is priced at $18.54, while NVCR trades at $16.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NVCR's P/E ratio is -10.56. In terms of profitability, BAX's ROE is -0.16%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, BAX is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NVCR's competition here
BAX vs PLSE Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, PLSE has a market cap of 1.7B. Regarding current trading prices, BAX is priced at $18.54, while PLSE trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas PLSE's P/E ratio is -22.72. In terms of profitability, BAX's ROE is -0.16%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BAX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check PLSE's competition here
BAX vs STAA Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, STAA has a market cap of 1.4B. Regarding current trading prices, BAX is priced at $18.54, while STAA trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas STAA's P/E ratio is -67.29. In terms of profitability, BAX's ROE is -0.16%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BAX is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STAA's competition here
BAX vs BLFS Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, BAX is priced at $18.54, while BLFS trades at $27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas BLFS's P/E ratio is -113.54. In terms of profitability, BAX's ROE is -0.16%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BAX is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check BLFS's competition here
BAX vs ATRC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ATRC has a market cap of 1.3B. Regarding current trading prices, BAX is priced at $18.54, while ATRC trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ATRC's P/E ratio is -262.00. In terms of profitability, BAX's ROE is -0.16%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, BAX is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check ATRC's competition here
BAX vs NNNN Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NNNN has a market cap of 1.3B. Regarding current trading prices, BAX is priced at $18.54, while NNNN trades at $28.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NNNN's P/E ratio is 197.97. In terms of profitability, BAX's ROE is -0.16%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, BAX is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NNNN's competition here
BAX vs AZTA Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, AZTA has a market cap of 1.1B. Regarding current trading prices, BAX is priced at $18.54, while AZTA trades at $23.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas AZTA's P/E ratio is -9.91. In terms of profitability, BAX's ROE is -0.16%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BAX is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check AZTA's competition here
BAX vs KMTS Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, KMTS has a market cap of 1.1B. Regarding current trading prices, BAX is priced at $18.54, while KMTS trades at $18.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas KMTS's P/E ratio is -3.45. In terms of profitability, BAX's ROE is -0.16%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, BAX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check KMTS's competition here
BAX vs QDEL Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, QDEL has a market cap of 927.4M. Regarding current trading prices, BAX is priced at $18.54, while QDEL trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas QDEL's P/E ratio is -0.76. In terms of profitability, BAX's ROE is -0.16%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BAX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check QDEL's competition here
BAX vs ATRI Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BAX is priced at $18.54, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BAX's ROE is -0.16%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BAX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATRI's competition here
BAX vs ANGO Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ANGO has a market cap of 462.8M. Regarding current trading prices, BAX is priced at $18.54, while ANGO trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ANGO's P/E ratio is -14.74. In terms of profitability, BAX's ROE is -0.16%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, BAX is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check ANGO's competition here
BAX vs OSUR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, OSUR has a market cap of 272M. Regarding current trading prices, BAX is priced at $18.54, while OSUR trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas OSUR's P/E ratio is -3.76. In terms of profitability, BAX's ROE is -0.16%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BAX is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check OSUR's competition here
BAX vs UTMD Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, UTMD has a market cap of 208.6M. Regarding current trading prices, BAX is priced at $18.54, while UTMD trades at $65.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas UTMD's P/E ratio is 19.39. In terms of profitability, BAX's ROE is -0.16%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check UTMD's competition here
BAX vs PDEX Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, PDEX has a market cap of 208.1M. Regarding current trading prices, BAX is priced at $18.54, while PDEX trades at $65.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas PDEX's P/E ratio is 17.95. In terms of profitability, BAX's ROE is -0.16%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BAX is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check PDEX's competition here
BAX vs SMTI Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, SMTI has a market cap of 192.2M. Regarding current trading prices, BAX is priced at $18.54, while SMTI trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas SMTI's P/E ratio is 349.50. In terms of profitability, BAX's ROE is -0.16%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BAX is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check SMTI's competition here
BAX vs INFU Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, INFU has a market cap of 182.8M. Regarding current trading prices, BAX is priced at $18.54, while INFU trades at $9.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas INFU's P/E ratio is 24.49. In terms of profitability, BAX's ROE is -0.16%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BAX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check INFU's competition here
BAX vs KRMD Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, KRMD has a market cap of 180.1M. Regarding current trading prices, BAX is priced at $18.54, while KRMD trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas KRMD's P/E ratio is -78.40. In terms of profitability, BAX's ROE is -0.16%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BAX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check KRMD's competition here
BAX vs STXS Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, STXS has a market cap of 178.9M. Regarding current trading prices, BAX is priced at $18.54, while STXS trades at $1.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas STXS's P/E ratio is -7.63. In terms of profitability, BAX's ROE is -0.16%, compared to STXS's ROE of -1.53%. Regarding short-term risk, BAX is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STXS's competition here
BAX vs NYXH Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NYXH has a market cap of 107.2M. Regarding current trading prices, BAX is priced at $18.54, while NYXH trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NYXH's P/E ratio is -1.16. In terms of profitability, BAX's ROE is -0.16%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, BAX is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NYXH's competition here
BAX vs MBOT Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, MBOT has a market cap of 89.8M. Regarding current trading prices, BAX is priced at $18.54, while MBOT trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas MBOT's P/E ratio is -7.58. In terms of profitability, BAX's ROE is -0.16%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BAX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check MBOT's competition here
BAX vs AKYA Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BAX is priced at $18.54, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BAX's ROE is -0.16%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, BAX is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check AKYA's competition here
BAX vs STSS Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, STSS has a market cap of 61.4M. Regarding current trading prices, BAX is priced at $18.54, while STSS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas STSS's P/E ratio is -0.02. In terms of profitability, BAX's ROE is -0.16%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BAX is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STSS's competition here
BAX vs ZTEK Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ZTEK has a market cap of 57.5M. Regarding current trading prices, BAX is priced at $18.54, while ZTEK trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ZTEK's P/E ratio is -8.91. In terms of profitability, BAX's ROE is -0.16%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, BAX is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check ZTEK's competition here
BAX vs DXR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, DXR has a market cap of 54.1M. Regarding current trading prices, BAX is priced at $18.54, while DXR trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas DXR's P/E ratio is 6.54. In terms of profitability, BAX's ROE is -0.16%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BAX is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check DXR's competition here
BAX vs OMIC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BAX is priced at $18.54, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BAX's ROE is -0.16%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BAX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check OMIC's competition here
BAX vs IGAP Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BAX is priced at $18.54, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BAX's ROE is -0.16%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BAX is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check IGAP's competition here
BAX vs POCI Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, POCI has a market cap of 42.5M. Regarding current trading prices, BAX is priced at $18.54, while POCI trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas POCI's P/E ratio is -8.59. In terms of profitability, BAX's ROE is -0.16%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BAX is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check POCI's competition here
BAX vs NEPH Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NEPH has a market cap of 39.5M. Regarding current trading prices, BAX is priced at $18.54, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NEPH's P/E ratio is 52.00. In terms of profitability, BAX's ROE is -0.16%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BAX is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NEPH's competition here
BAX vs MLSS Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, MLSS has a market cap of 34.7M. Regarding current trading prices, BAX is priced at $18.54, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas MLSS's P/E ratio is -6.56. In terms of profitability, BAX's ROE is -0.16%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BAX is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check MLSS's competition here
BAX vs HBIO Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, HBIO has a market cap of 29.3M. Regarding current trading prices, BAX is priced at $18.54, while HBIO trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas HBIO's P/E ratio is -3.02. In terms of profitability, BAX's ROE is -0.16%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BAX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check HBIO's competition here
BAX vs SDC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BAX is priced at $18.54, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas SDC's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BAX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check SDC's competition here
BAX vs EKSO Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, BAX is priced at $18.54, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas EKSO's P/E ratio is -2.31. In terms of profitability, BAX's ROE is -0.16%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, BAX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check EKSO's competition here
BAX vs IVC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BAX is priced at $18.54, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas IVC's P/E ratio is -0.79. In terms of profitability, BAX's ROE is -0.16%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BAX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check IVC's competition here
BAX vs ZJYL Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ZJYL has a market cap of 24.3M. Regarding current trading prices, BAX is priced at $18.54, while ZJYL trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ZJYL's P/E ratio is 15.50. In terms of profitability, BAX's ROE is -0.16%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BAX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check ZJYL's competition here
BAX vs RVP Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, RVP has a market cap of 19.9M. Regarding current trading prices, BAX is priced at $18.54, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas RVP's P/E ratio is -3.02. In terms of profitability, BAX's ROE is -0.16%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BAX is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check RVP's competition here
BAX vs FEMY Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, FEMY has a market cap of 10.8M. Regarding current trading prices, BAX is priced at $18.54, while FEMY trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas FEMY's P/E ratio is -1.53. In terms of profitability, BAX's ROE is -0.16%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BAX is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check FEMY's competition here
BAX vs RGNT Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, RGNT has a market cap of 7M. Regarding current trading prices, BAX is priced at $18.54, while RGNT trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas RGNT's P/E ratio is -0.07. In terms of profitability, BAX's ROE is -0.16%, compared to RGNT's ROE of N/A. Regarding short-term risk, BAX is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check RGNT's competition here
BAX vs NXGL Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NXGL has a market cap of 5.4M. Regarding current trading prices, BAX is priced at $18.54, while NXGL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NXGL's P/E ratio is -1.46. In terms of profitability, BAX's ROE is -0.16%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BAX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NXGL's competition here
BAX vs NSTG Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BAX is priced at $18.54, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BAX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NSTG's competition here
BAX vs LUCY Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, LUCY has a market cap of 3.8M. Regarding current trading prices, BAX is priced at $18.54, while LUCY trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas LUCY's P/E ratio is -0.62. In terms of profitability, BAX's ROE is -0.16%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BAX is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check LUCY's competition here
BAX vs POAI Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BAX is priced at $18.54, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas POAI's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BAX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check POAI's competition here
BAX vs NXGLW Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, NXGLW has a market cap of 3.1M. Regarding current trading prices, BAX is priced at $18.54, while NXGLW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas NXGLW's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BAX is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check NXGLW's competition here
BAX vs MHUA Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BAX is priced at $18.54, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BAX's ROE is -0.16%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, BAX is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check MHUA's competition here
BAX vs GMVD Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $18.54, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.16%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check GMVD's competition here
BAX vs GMVDW Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $18.54, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check GMVDW's competition here
BAX vs AVGR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BAX is priced at $18.54, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BAX's ROE is -0.16%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BAX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check AVGR's competition here
BAX vs STSSW Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, STSSW has a market cap of 887.9K. Regarding current trading prices, BAX is priced at $18.54, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas STSSW's P/E ratio is -0.04. In terms of profitability, BAX's ROE is -0.16%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, BAX is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check STSSW's competition here
BAX vs GCTK Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, GCTK has a market cap of 377.6K. Regarding current trading prices, BAX is priced at $18.54, while GCTK trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas GCTK's P/E ratio is 0.11. In terms of profitability, BAX's ROE is -0.16%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BAX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check GCTK's competition here
BAX vs LUCYW Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BAX is priced at $18.54, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BAX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check LUCYW's competition here
BAX vs WOK Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, WOK has a market cap of 610. Regarding current trading prices, BAX is priced at $18.54, while WOK trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas WOK's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to WOK's ROE of -0.07%. Regarding short-term risk, BAX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.Check WOK's competition here
BAX vs APR Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, APR has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas APR's P/E ratio is 22.59. In terms of profitability, BAX's ROE is -0.16%, compared to APR's ROE of +9.81%. Regarding short-term risk, BAX is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check APR's competition here
BAX vs IVTY Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas IVTY's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BAX is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check IVTY's competition here
BAX vs IIN Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas IIN's P/E ratio is 226.45. In terms of profitability, BAX's ROE is -0.16%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BAX is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check IIN's competition here
BAX vs ATRS Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BAX's ROE is -0.16%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BAX is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ATRS's competition here
BAX vs HRC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas HRC's P/E ratio is 41.92. In terms of profitability, BAX's ROE is -0.16%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check HRC's competition here
BAX vs ARTC Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ARTC has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ARTC's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to ARTC's ROE of N/A. Regarding short-term risk, BAX is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ARTC's competition here
BAX vs ALOG Comparison June 2026
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 9.6B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BAX is priced at $18.54, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -9.71, whereas ALOG's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BAX is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.Check ALOG's competition here